MARKET

URGN

URGN

Urogen Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

23.75
+0.28
+1.19%
Closed 16:00 06/01 EDT
OPEN
23.45
PREV CLOSE
23.47
HIGH
24.23
LOW
22.88
VOLUME
242.19K
TURNOVER
--
52 WEEK HIGH
38.03
52 WEEK LOW
13.12
MARKET CAP
520.96M
P/E (TTM)
-4.1053
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average URGN stock price target is 46.14 with a high estimate of 59.00 and a low estimate of 30.00.

EPS

URGN News

More
UroGen Pharma to Present at Jefferies Virtual Healthcare Conference
Business Wire · 23h ago
Cassava Slumped Last Week After Bad Data, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 05/19 19:12
UroGen Pharma Announces First Presentation of Data from Phase 2b Study of UGN-102 in Patients with Difficult to Treat Type of Bladder Cancer
Business Wire · 05/15 14:01
UroGen Announces Positive Data from Pivotal OLYMPUS Trial Evaluating Jelmyto in Patients with Low-Grade Upper Tract Urothelial Cancer
Business Wire · 05/15 14:00
Urogen's mitomycin shows positive effect in mid-stage bladder cancer study
Seeking Alpha - Article · 05/15 13:40
UroGen Highlights Presentation Of Data From Phase 2b Study Of UGN-102 In Patients With Difficult-To-Treat Type Of Bladder Cancer: 65% Complete Response, 97% Remained Disease Free At 6 Months, 86% At 9 Months, 85% At 12 Months
UroGen Pharma Ltd. (NASDAQ:URGN) today announced the presentation of positive interim data from the Phase 2b OPTIMA II trial evaluating the safety and efficacy of investigational agent UGN-102 (mitomycin) for
Benzinga · 05/15 13:08
UroGen Reports Data From Pivotal OLYMPUS Trial Evaluating Jelmyto In Patients With Low-Grade Upper Tract Urothelial Cancer
Benzinga · 05/15 13:04
UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/10 13:38

Industry

Biotechnology & Medical Research
+0.07%
Pharmaceuticals & Medical Research
-0.77%

Hot Stocks

Symbol
Price
%Change

About URGN

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidates include Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). Its platform technologies include: RTGel and Immunotherapy.
More

Webull offers kinds of Urogen Pharma Ltd stock information, including NASDAQ:URGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, URGN stock news, and many more online research tools to help you make informed decisions.